Lactobacillus paracasei LCQ-1 and application thereof
By providing Lactobacillus paracasei LCQ-1, the problem of lack of effective lactic acid strains in the prior art was solved, the prevention and treatment of diarrhea was achieved, and effective antagonism of E. coli, Enterococcus faecalis and Salmonella were demonstrated. Significant effects in preventing and treating diarrhea.
Patent Information
- Application Number
- CN202410936376.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-12-06
AI Technical Summary
There is a lack of lactic acid strains with significant probiotic properties in the prior art, which is difficult to effectively prevent and treat diarrhea, and has strong antagonism ability to pathogenic bacteria such as E. coli, Enterococcus faecalis and Salmonella.
It provides a Lactobacillus paracasei LCQ-1, which has acid resistance, bile salt resistance and strong antagonism, can colonize and effectively inhibit pathogenic bacteria in the body, and is used to prepare products for preventing and treating diarrhea.
LCQ-1 showed good safety, acid resistance, bile salt resistance and strong antagonism, significantly prevented and treated diarrhea, and had good effects on E. coli, Enterococcus faecalis and Salmonella.
Smart Images

Figure CN119081916A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and more specifically to a strain of Lactobacillus paracasei LCQ-1 and application thereof. Background Art
[0002] Lactic acid bacteria (LAB) are a special type of Gram-positive bacteria that usually participate in natural fermentation and are widely used in the food and pharmaceutical manufacturing industries. It is widely present in nature and has rich species diversity, including at least 23 genera and more than 200 species. Lactic acid bacteria are closely related to human life and are an indispensable part of the intestinal microorganisms of humans or animals. Studies have shown that lactic acid bacteria have beneficial physiological effects such as regulating intestinal flora, lowering cholesterol, and enhancing immunity. With the continuous development of alternatives to antibiotic drugs, lactic acid bacteria have attracted great attention from domestic and foreign scientific researchers in the past few years. According to the latest definition of the World Health Organization, lactic acid bacteria, as an applicable microorganism, can give different probiotic effects to the host. The probiotic properties of lactic acid bacteria benefit from the competition of lactic acid bacteria with pathogens for energy sources, thereby inhibiting the growth and development of pathogens. Lactic acid bacteria therapy aims to change the composition of the microbiome, inhibit harmful pathogens, and form a microbial community that is beneficial to the host. To this end, we can use the colonization characteristics of lactic acid bacteria to reduce the formation of dominant flora of potential pathogens and play a role in preventing the occurrence of diseases.
[0003] Therefore, providing more lactic acid bacteria with probiotic properties is a problem that those skilled in the art need to solve urgently. Summary of the invention
[0004] In view of this, the present invention provides a strain of Lactobacillus paracasei LCQ-1 and application thereof.
[0005] In order to achieve the above object, the present invention adopts the following technical solution:
[0006] A strain of Lactobacillus paracasei LCQ-1, the LCQ-1 preservation number is CGMCC NO.30466, preserved in the General Microbiology Center of China Microorganism Culture Collection Administration, the preservation address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is April 28, 2024, and the classification name is Lactobacillus paracasei.
[0007] Another object of the present invention is to provide the use of the above-mentioned Lactobacillus paracasei LCQ-1 in the preparation of products for preventing and treating diarrhea.
[0008] Another object of the present invention is to provide the use of the above-mentioned Lactobacillus paracasei LCQ-1 in antagonizing pathogenic bacteria, wherein the pathogenic bacteria are one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
[0009] Another object of the present invention is to provide the use of the above-mentioned Lactobacillus paracasei LCQ-1 in the preparation of a pathogenic bacteria antagonistic product, wherein the pathogenic bacteria is one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
[0010] Another object of the present invention is to provide a drug for preventing and treating diarrhea, comprising the above-mentioned Lactobacillus paracasei LCQ-1.
[0011] Another object of the present invention is to provide a drug for antagonizing pathogenic bacteria, comprising the above-mentioned Lactobacillus paracasei LCQ-1; and the pathogenic bacteria are one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
[0012] Beneficial effects: The Lactobacillus paracasei LCQ-1 of the present invention has been proven to have good safety, acid resistance, bile salt resistance, strong in vivo colonization ability, good antagonism against Escherichia coli, Enterococcus faecalis and Salmonella, and good effect of preventing and treating diarrhea. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0014] Figure 1 Schematic diagram of the colony of strain LCQ-1 of the present invention.
[0015] Figure 2 Schematic diagram of Gram staining of strain LCQ-1 of the present invention.
[0016] Figure 3 This is the phylogenetic tree of the strain LCQ-1 of the present invention.
[0017] Figure 4 This is the growth curve of the strain LCQ-1 of the present invention.
[0018] Figure 5 These are the results of the adhesion cell experiment of the strain LCQ-1 of the present invention.
[0019] Figure 6 These are the results of the Escherichia coli challenge experiment after mice were intragastrically administered with the strain LCQ-1.
[0020] Figure 7These are the results of in vitro safety tests of the strain LCQ-1 of the present invention; wherein, A is the result of the hemolytic activity assay of LCQ-1, B is the result of the gelatinase activity assay of LCQ-1, C is the result of the mucin degradation activity assay of LCQ-1, D is the result of the tyrosine production test (left: control group, right: agar medium with tyrosine added), E is the result of the ornithine production test (left: control control group, right: agar medium with ornithine added), and F is the result of the histidine production test (left: control control group, right: agar medium with histidine added).
[0021] Figure 8 The results of amplification of drug resistance genes, virulence genes and decarboxylase genes of the strain LCQ-1 of the present invention are shown; wherein A is the PCR electrophoresis diagram of amino acid decarboxylase gene of LCQ-1 genomic DNA, and the gel wells from left to right are M: Maker DL2000, 1-6: hdc1, hdc2, hdc3, tdc1, tdc2, tdc3 genes, 7-12: negative control; B is the PCR electrophoresis diagram of virulence gene of LCQ-1 genomic DNA, and the gel wells from left to right are M: Maker DL2000, 1-7: gelE, cylA, cylB, cylM, asal, ace, esp genes, 8-14: negative control; C is the PCR electrophoresis diagram of drug resistance gene of LCQ-1 genomic DNA, and the gel wells from left to right are M: Maker DL2000,1-12: aph, ant(6), aacI, accII, tet, vanI, vanII, erm, bIaI, bIaII, suI, qnr genes,13-24: negative control.
[0022] Fig. 9 The changes in body mass index of mice fed with the strain LCQ-1 of the present invention (*P<0.05; **P<0.01; ***P<0.001, ns, no significant difference).
[0023] Fig.10 Serological indexes of mice fed with the strain LCQ-1 of the present invention for 28 days, wherein A is the direct bilirubin (DBIL-Z), total bilirubin (TBIL-Z), and alanine aminotransferase (ALT) indexes of mouse liver function; B is the creatinine (CREA), uric acid (UA), and urea (BUN) indexes of mouse renal function; C is the triglyceride (TG), glucose (GLU-YA), and total cholesterol (TC) indexes of mouse; (*P<0.05; **P<0.01; ***P<0.001, ns, no significant difference. DETAILED DESCRIPTION
[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0025] The growth conditions of the bacterial strains and cells involved in the present invention are:
[0026] Lactobacillus paracasei LCQ-1 and Lactobacillus rhamnosus were inoculated in MRS liquid medium and cultured anaerobically at 37°C; indicator bacteria [Escherichia coli, Enterococcus faecalis and Salmonella] were inoculated in BHI liquid medium and cultured in a common incubator at 37°C. Caco-2 cells were cultured in DMEM (containing 10% fetal bovine serum, 50 μg / mL streptomycin and 50 μg / mL penicillin) and placed in a CO2 incubator.
[0027] The sources and feeding conditions of the experimental animals involved in the present invention are as follows:
[0028] Kunming mice were purchased from Beijing Sibeifu Biotechnology Co., Ltd. (Beijing, China). The mice were housed in a specific pathogen-free environment, and all animal experimental procedures were approved by the Experimental Animal Ethics Committee of Hebei Science and Technology Normal University (Qinhuangdao, China) (Xiao Ke Zi
[2020] No. 17). Female Kunming mice aged 6–8 weeks were used for LD 50 For testing, 6-8 week-old Kunming female mice and male mice were used for acute challenge test, 28-day feeding test and animal diarrhea prevention test.
[0029] Example 1
[0030] 1. Isolation and screening of strain LCQ-1
[0031] Fresh cattle feces samples were collected from Benchi Animal Husbandry (Qinhuangdao, Hebei Province), stored at 4°C and sent to the laboratory. 1 g of sample was used to prepare gradient dilutions in 2 mL of sterile saline buffer and incubated in an anaerobic incubator at 37°C for 36 h.
[0032] 2. Identification of strain LCQ-1
[0033] Purify single colonies with smooth edges and milky white dots (see Appendix Figure 1 ), Gram staining (see Appendix Figure 2) and 16s rDNA gene sequencing. The sequencing results were compared with the relevant sequences in the Genbank database, and the Blast program was used for multiple comparisons. Mega7.0 was used to construct an evolutionary tree (see Appendix Figure 3 ).
[0034] Based on the above results, LCQ-1 was identified as Lactobacillus paracasei.
[0035] 3. Storage of strain LCQ-1
[0036] The strain LCQ-1 was deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with the deposit address at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the deposit date: April 28, 2024, the deposit number: CGMCC NO.30466, and the classification name: Lactobacillus paracasei.
[0037] Example 2
[0038] In vitro probiotic properties of strain LCQ-1
[0039] 1. Growth curve of strain LCQ-1
[0040] The strain LCQ-1 was inoculated into fresh MRS liquid medium and cultured anaerobically at 37°C. The bacteria were counted every 2 hours starting at 0 h. The bacterial growth curve was plotted with time as the horizontal axis and the logarithm of the bacterial number as the vertical axis (see Appendix). Figure 4 ).
[0041] From the attached Figure 1 It can be seen that strain LCQ-1 began to enter the logarithmic growth phase after 2 hours of culture, and continued to grow slowly after 10 hours of culture. It reached the stable phase after 12 hours, and no decline phase was observed after 48 hours.
[0042] 2. Antibacterial activity analysis
[0043] The concentration of indicator bacteria (Escherichia coli (SUB14457113), Enterococcus faecalis (ATCC33186), and Salmonella (CVCC50336)) was adjusted to 1×10 7 CFU / mL, 200 μL was evenly spread on the BHI agar plate, and 200 μL of the cell-free supernatant (CFS) of the strain LCQ-1 filtered by a 0.22 μm microporous membrane was added into the well by the punching method. Incubate in a 37°C incubator for 12 h, and observe and record the diameter of the inhibition zone (see Table 1).
[0044] Table 1 Antimicrobial spectrum
[0045]
[0046] Note: 1.+++, inhibition zone diameter: 18.00-22.00mm; ++++, greater than 22.00mm; the inhibition zone diameter includes the punch diameter (10.00mm).
[0047] The diameters of the inhibition zones of strain LCQ-1 against Enterococcus faecalis, Escherichia coli and Salmonella were all greater than 18.00 mm. Strain LCQ-1 showed significant antibacterial activity.
[0048] 3. Acid production test
[0049] The strain LCQ-1 was cultured in an anaerobic incubator at 37°C in MRS medium for 48 hours, and the pH value of its CFS was measured. MRS liquid medium was used as the control group, and the pH value was measured every 8 hours for 48 hours. The experiment was repeated 3 times (see Table 2).
[0050] Table 2 Acid production capacity
[0051]
[0052] It can be seen that after strain LCQ-1 was cultured anaerobicly at 37°C for 48 hours, the pH value of the supernatant was stable at 3.60-3.67, which was acidic. The results confirmed that strain LCQ-1 showed a strong acid production ability (P < 0.05).
[0053] 4. Acid resistance, bile salt resistance and high temperature resistance test
[0054] MRS liquid medium was added to four 50 mL centrifuge tubes, and the pH of the MRS liquid medium was adjusted to 1, 2, 3, and 4. The strain LCQ-1 was inoculated into the medium with different pH values at a bacterial amount of 2%, and anaerobically cultured at 37°C for 4 hours, and the bacteria were counted every 1 hour. The experiment was repeated 3 times (see Table 3).
[0055] Take 4 50mL centrifuge tubes, prepare MRS liquid culture medium with bile salt concentrations of 0.1%, 0.2% and 0.3%, inoculate strain LCQ-1 into the culture medium with different bile salt concentrations at a bacterial count of 2%, culture anaerobically at 37°C for 4 hours, and count the bacteria. The experiment was repeated 3 times (see Table 3).
[0056] The strain LCQ-1 was inoculated into MRS liquid medium and cultured anaerobically at 37°C. After 4 hours, the bacteria were treated at high temperatures in a water bath at 50°C, 60°C, and 70°C. The bacteria were counted after 5 minutes, 10 minutes, and 15 minutes of treatment, respectively. The experiment was repeated 3 times (see Tables 3 and 4).
[0057] Table 3 Acid resistance, bile salt resistance and high temperature resistance
[0058]
[0059] Note: +, positive; -, negative; w, weak positive;
[0060] Table 4 Effect of high temperature conditions on LCQ-1
[0061]
[0062] The ability of probiotics to tolerate gastric acid and bile is a key factor in their survival in the gastrointestinal tract. The strain LCQ-1 of the present invention can survive at high temperatures of 50°C, 60°C, and 70°C, and has significant high temperature resistance. Interestingly, this study found that the strain LCQ-1 can even continue to grow at 50°C. The strain LCQ-1 can tolerate a bile salt solution with a concentration of 0.1%. In addition, the strain LCQ-1 can grow at pH 3.0 to pH 4.0, and has good acid resistance.
[0063] 5. Surface properties of strains
[0064] (1) Hydrophobicity test: The surface hydrophobicity of strain LCQ-1 was tested by xylene method. The brief steps were as follows: the overnight cultured strain LCQ-1 was centrifuged, washed with PBS and resuspended, and the OD 600 to 0.6. Mix 1 mL of xylene with 3 mL of bacterial suspension. Let stand for 1 hour. When two phases separate, measure the OD of the aqueous phase. 600 The control group was 1 mL of xylene and 3 mL of PBS buffer. The percentage of hydrophobicity on the bacterial surface was calculated and recorded using the following formula:
[0065] Bacteria surface hydrophobicity (%) = (A0-A1) / A0×100%
[0066] A0 represents the OD value of the bacterial suspension in a static state after mixing for 0 min; A1 represents the OD value of the bacterial suspension in a static state after mixing for 1 h.
[0067] The results are shown in Table 7.
[0068] (2) Self-aggregation test: The overnight cultured strain LCQ-1 was centrifuged, washed with PBS and resuspended. The OD 600 Take 5 mL of bacterial suspension, let it stand at room temperature for 2 hours, and take 3 mL of the upper liquid to measure the OD 600 , the self-aggregation rate of strain LCQ-1 was calculated by the following formula:
[0069] Self-aggregation rate (%) = (A0-A2) / A0×100%
[0070] A0 is the OD value of the bacterial suspension in a static state for 0 min; A2 is the OD value of the bacterial suspension in a static state for 2 h.
[0071] The results are shown in Table 7.
[0072] (3) Coaggregation test: The overnight cultured strains LCQ-1, E. coli, and Salmonella were centrifuged, washed with PBS, and resuspended. The OD 600 Mix and shake 2 mL of indicator bacteria Escherichia coli and Salmonella LCQ-1, let it stand for 2 hours, and take 3 mL of the upper liquid to measure the OD 600 The coaggregation rate of strain LCQ-1 was calculated by the following formula.
[0073] Coagulation rate (%) = (A0-A3) / A0×100%
[0074] A0 is the OD value of the bacterial suspension after mixing for 0 min; A3 is the OD value of the bacterial suspension after mixing for 2 h.
[0075] The results are shown in Table 7.
[0076] (4) Cell adhesion test: Caco-2 cells were used to measure the adhesion ability of strain LCQ-1. The Caco-2 cell concentration was adjusted to 8×10 5 cell / mL, and 1 mL of Caco-2 cells was added to a 12-well cell culture plate. The concentrations of strains LCQ-1, Lactobacillus rhamnosus, Escherichia coli, and Salmonella were adjusted to 8 × 10 7 CFU / mL, add cells at a multiplicity of infection (MOI) of 100, centrifuge at 1000 rpm / min for 5 min, and incubate at 37°C in a 5% CO2 incubator for 2 h. Wash 3 times with PBS, lyse cells with 1 mL of 1% TritonX-100 for 8 min, and dilute the lysate in multiples for counting (see Appendix Figure 5 ).
[0077] Adhesion rate = (number of adherent bacteria / number of infected bacteria in the well) × 100%.
[0078] Table 7 Surface properties of LCQ-1
[0079]
[0080] Whether probiotics can bind to the surface receptors of the intestinal mucosa depends on the surface properties of the strain. Strains with high hydrophobicity usually have strong adhesion to mucosal cells. In addition, in addition to adhesion, probiotics also need to reach a sufficient number through self-aggregation to fully exert their probiotic effects. Co-aggregation is also the basis for lactic acid bacteria to form a biological barrier to prevent pathogenic bacteria from colonizing the intestine. Hydrophobicity, self-aggregation and co-aggregation ability are the main reference indicators for evaluating the surface properties of strain LCQ-1. From the results in Table 7, it can be seen that the hydrophobicity and self-aggregation of strain LCQ-1 are both higher than 50%. By measuring the co-aggregation of strain LCQ-1 with Escherichia coli and Salmonella, it was shown that strain LCQ-1 has a strong aggregation effect on both pathogenic bacteria, and the aggregation rate is more than 60%.
[0081] Example 3
[0082] In vivo probiotic properties of strain LCQ-1
[0083] Twenty female Kunming mice aged 6 to 8 weeks were randomly divided into two groups (n = 10). The mice in group 1 were intragastrically inoculated with LCQ-1 at a dose of 200 μL / mouse and a bacterial solution concentration of 10 10 CFU / mL. The mice in group 2 were gavaged with saline solution at a dose of 200 μL / mouse. The gavage was continued for 14 days. After 14 days, the mice in group 1 (gavaged with LCQ-1) and group 2 (gavaged with saline solution) were simultaneously infected with K99 via the peritoneal route. The results showed (see Appendix Figure 6 ), the survival rate of group 1 was 80% within 14 days, and the survival rate of group 2 was 50% within 14 days. The results showed that strain LCQ-1 had a good preventive effect on diarrhea mice.
[0084] Example 4
[0085] In vitro safety test of strain LCQ-1
[0086] 1. Hemolytic test
[0087] The LCQ-1 bacterial culture was inoculated (5 μL) on a blood agar plate and cultured anaerobically at 37°C for 24 h. The bacterial growth area around the plate was observed (see Appendix for results). Figure 7 Staphylococcus aureus was used as a positive control.
[0088] 2. Gelatinase test
[0089] The bacterial culture of strain LCQ-1 was inoculated (5 μL) on a nutrient gelatin agar plate and cultured anaerobically at 37°C for 24 h (see attached for results). Figure 7 Middle B). Observe the clear area of bacterial growth around the plate.
[0090] 3. Mucin degradation test
[0091] The bacterial culture of strain LCQ-1 was inoculated (5 μL) on MRS agar containing 0.3% (w / v) mucin, incubated anaerobically at 37°C for 24 h, and stained with Coomassie Brilliant Blue dissolved in 3.5 M acetic acid for 30 min. The plate was then washed with 1.2 M acetic acid until a mucin lysis zone (discoloration halo) appeared around the growth (see attached for results). Figure 7 Middle C).
[0092] 4. Biogenic amine production test
[0093] Amino acid decarboxylase agar was used to evaluate the production of biogenic amines such as tyramine, histamine, and putrescine. The precursor amino acids tyrosine, histidine, and ornithine were added to the amino acid decarboxylase agar to test whether the isolate LCQ-1 produced enzymes that decomposed the above substrates. A bacterial culture of strain LCQ-1 was inoculated (5 μL) on the decarboxylase agar and incubated anaerobically at 37°C for 24 h. The culture medium was considered positive when the color changed from yellow to purple (see attached for results). Figure 7 (in DF).
[0094] The above test results showed that the isolate LCQ-1 had no hemolytic activity, no gelatinase activity, and no mucin degradation activity. The results of the biogenic amine production test showed that the isolate LCQ-1 had no tyrosinase and ornithine activity, but had histidase activity.
[0095] 5. Drug sensitivity test
[0096] The KB method was used to detect the drug resistance of strain LCQ-1, and 18 drugs were selected, namely: lincomycin, florfenicol, enrofloxacin, sulfadimethoxine, tilmicosin, cephalexin, kanamycin, doxycycline, oxytetracycline, cotrimoxazole, spectinomycin, sulfadimethoxine, ceftriaxone, amikacin, penicillin, ciprofloxacin, amoxicillin, and neomycin. The overnight cultured LCQ-1 bacterial solution was spread on MRS agar, and the drug sensitivity sheet was attached to the plate after coating. The plate was anaerobically cultured at 37°C for 24 hours, the diameter of the inhibition zone was measured, and the results were determined according to the NCCLS drug sensitivity test standard (the results are shown in Table 9).
[0097] Table 9 Antibiotic susceptibility of LCQ-1
[0098]
[0099] It can be seen that strain LCQ-1 is resistant to six antibiotics, including enrofloxacin, cephalexin, kanamycin, co-trimoxazole, sulfamethoxazole, and amikacin; it is intermediately resistant to seven antibiotics, including lincomycin, sulfadimethoxine, tilmicosin, oxytetracycline, spectinomycin, ceftriaxone, and neomycin; and it is sensitive to five antibiotics, including florfenicol, doxycycline, penicillin, ciprofloxacin, and amoxicillin.
[0100] 6. PCR detection of drug resistance genes, virulence genes and decarboxylase genes
[0101] The genomic DNA of strain LCQ-1 was used as a template to perform PCR reaction to detect whether strain LCQ-1 contained drug resistance genes, virulence genes, and decarboxylase genes. The primer sequences and annealing temperatures for drug resistance genes, virulence genes, and decarboxylase genes are shown in Table 10.
[0102] Table 10
[0103]
[0104]
[0105] The electrophoresis results of PCR amplification products are shown in the attached Figure 8 The results showed that no amino acid decarboxylase gene and virulence gene were detected; a total of three drug-resistant genes, aph, vanl, and erm, were detected.
[0106] In summary, the in vitro safety test of this embodiment proves that no amino acid decarboxylase gene and virulence gene were detected in strain LCQ-1; a total of 3 drug resistance genes were detected, namely aph, vanl, and erm. LCQ-1 is resistant to 6 antibiotics including enrofloxacin, cephalexin, kanamycin, cotrimoxazole, sulfamethoxazole, and amikacin; it is intermediately resistant to 7 antibiotics including lincomycin, sulfadimethoxine, tilmicosin, oxytetracycline, spectinomycin, ceftriaxone, and neomycin; it is sensitive to 5 antibiotics including florfenicol, doxycycline, penicillin, ciprofloxacin, and amoxicillin. Strain LCQ-1 has no hemolytic activity and gelatinase activity, does not dissolve mucin, has no tyrosinase and ornithine activity, and has histidase activity. The above results prove that strain LCQ-1 has good safety.
[0107] Example 5
[0108] In vivo safety test of strain LCQ-1
[0109] 1. Acute challenge test
[0110] The study was conducted according to the method in GB15193.3-2014 "Acute Oral Toxicity Test". Ten female Kunming mice aged 6 to 8 weeks were randomly divided into two groups (n = 5). One group was gavaged with the isolate LCQ-1 at a dose of 10 9 CFU / mouse; another group was gavaged with normal saline at a dose of 200 μL / mouse for 7 consecutive days. During the feeding period, sufficient mouse food and purified water were ensured, and the clinical manifestations of the animals were observed and recorded daily.
[0111] The results showed that the test mice did not show any obvious signs of poisoning and no deaths occurred during the observation period.
[0112] 2. 28-day feeding trial
[0113] The experimental study was conducted with reference to GB15193.22-2014 "28-day oral toxicity test". Twenty Kunming mice aged 6 to 8 weeks were randomly divided into 4 groups (n = 5). The mice in groups 1, 2 and 3 were gavaged with the isolated strain LCQ-1 at a dose of 200 μl / mouse. The concentration of the bacterial solution was 10 8 CFU / mL, 10 9 CFU / mL and 10 10 CFU / mL. The mice in group 4 were gavaged with normal saline at a dose of 200 μl / mouse. The gavage was continued for 28 days. The experimental groups are shown in Table 11.
[0114] Table 11
[0115]
[0116]
[0117] Determination of organ index: After 28 days of feeding, the mice were dissected the next day. Carefully and quickly remove the heart, liver, spleen, lungs, and kidneys with a scalpel, observe the color and obvious changes of each organ, and place them in a sterile dish. Wash the excess tissue with physiological saline and dry it with filter paper, weigh the mass, and calculate the mouse organ index according to the following formula.
[0118] Organ index (%): organ mass (g) / mouse body mass (g) x 100%.
[0119] Bacterial translocation test: After 28 days of feeding, the mice were dissected the next day. The heart, liver, spleen, lungs, and kidneys were carefully and quickly removed with a scalpel. Each organ was cut open with a scalpel under sterile conditions. The organ section was scraped with a bacterial loop, and then streaked on MRS agar. The culture was then anaerobically cultured at 37°C for 24 hours. Whether there was bacterial colony growth on the culture medium was observed.
[0120] Analysis of animal blood biochemical indexes: After 28 days of feeding, blood was collected from the eyeballs the next day. The serum was collected in a centrifuge tube and tested using an automatic biochemical analyzer (Jiangsu Su Ke Biotechnology Co., Ltd., China) to evaluate the parameters of liver function, kidney function, blood sugar, blood lipids and cholesterol levels.
[0121] Histological observation: After 28 days of feeding, the mice were dissected the next day. The ileum segment was carefully and quickly removed with a scalpel, rinsed with saline, and finally immersed in 10% buffered formaldehyde solution for tissue fixation. It was sent to Shijiazhuang Fengyue Biotechnology Co., Ltd. for histopathological section HE staining. According to the description of Alvim et al., the histological evaluation of the ileum segment was performed: significant histological changes were measured: (i) the degree of mononuclear and multinuclear cell infiltration in the lamina propria, (ii) epithelial ulceration and erosion, (iii) edema in the lamina propria, (iv) congestion, and (v) changes in mucosal structure.
[0122] 28-day feeding test results:
[0123] (1) The mice in each group were in good spirits, and their food intake, water intake, and excretion were normal (see Table 12). The mice in each group gained an average of 8-9 g in 28 days after oral gavage (see Appendix Fig. 9 ), proving that different concentrations of the isolated strain LCQ-1 all promote the growth of mice. After scraping the organ section with a bacterial loop and streaking, no target colonies appeared, and no bacterial translocation occurred in any group. After 28 days of feeding, the mice were dissected, and the organs of the mice in each group had normal color and no lesions were found. There was no significant difference in the organ index of the experimental group of mice compared with the control group (P>0.05) (see Table 13), proving that the strains within the gavage experimental dose range had no adverse effects on the important organs of the body, and the isolated strain LCQ-1 was identified as a safe strain.
[0124] Table 12 Observation items of mouse poisoning symptoms
[0125]
[0126] Table 13 Mouse organ index
[0127]
[0128] (2) The serum biochemical indexes of mice fed for 28 days showed that the levels of ALT, T-BIL, and D-BII in the experimental group were slightly higher than those in the control group (see Appendix Fig.10 A), but there was no significant difference (P>0.05), indicating that LCQ-1 had no damaging effect on the integrity of mouse liver cells and liver function. Similarly, the isolated strain LCQ-1 had no effect on the nitrogen metabolism and renal excretion function of mice. There was no significant difference in the levels of CREA, BUN, and UA between the experimental group and the control group (P>0.05) (see Appendix Fig.10 There was no significant difference in total cholesterol (TC) and glucose (GLU) between the experimental groups and the control group (P>0.05) (see Appendix Fig.10 C); although the triglyceride (TG) of mice changed slightly, there was no significant difference compared with the control group (P>0.05) (see Appendix Fig.10 Middle C); This indicates that the test strain has no effect on blood glucose and blood lipids in mice.
[0129] Histopathological analysis: The intestinal morphology, villus length, and crypt depth of the three probiotic groups (group 1, group 2, and group 3) were observed under a microscope compared with the control group (group 4). No pathological phenomena were found, such as intestinal ulcers, inflammatory cell infiltration, and intestinal mucosal degeneration or necrosis.
[0130] 3. Mouse LD 50 Determination of
[0131] Thirty female Kunming mice aged 6 to 8 weeks were randomly divided into 6 groups (n = 5). The first 5 groups of mice were intraperitoneally injected with graded dilutions of K99 at a dose of 5.56 × 10 8 -5.56×10 4 CFU / mouse; the remaining group was intraperitoneally injected with an equal volume of PBS. The number of mice that died was observed and recorded within 14 days, and the LD of E. coli K99 was calculated according to the Koch method. 50 , where Xk is the highest logarithmic dose, i is the difference between two adjacent logarithmic doses, and ∑p is the total mortality rate of each test group (see Table 14).
[0132] logLD 50 =Xk-i(∑p-0.5)
[0133] Table 14K99 LD 50 Determination
[0134]
[0135] The LD of isolate LCQ-1 was calculated. 50 >10g / kg. The LD50 of Escherichia coli K99 is 4.4×10 7 CFU / piece.
[0136] In summary, this embodiment proves that strain LCQ-1 is non-pathogenic to mice through acute challenge test. Mice were fed with LCQ-1 continuously for 28 days, and bacterial translocation experiments, organ index and serum biochemical index analysis, pathological tissue observation, and Escherichia coli challenge experiment were performed to analyze the probiotic properties of the strain from the in vivo level. The results showed that strain LCQ-1 was not lethal to mice, no bacterial translocation occurred, no lesions were found in the organs of mice, and no significant changes occurred in serum biochemical indicators. The above results show that the isolate is safe for mice at the in vivo level. After the feeding was completed, mice were intraperitoneally injected with Escherichia coli K99 to attack the virus. The survival rate of mice in the experimental group reached 80%, and the survival rate of mice not fed with Lactobacillus paracasei LCQ-1 was only 50%, indicating that Lactobacillus paracasei LCQ-1 has a good preventive effect on diarrheal mice.
[0137] The data of each embodiment of the present invention were analyzed by one-way ANOVA between groups using SPSS26, and post hoc LSD multiple comparisons were performed. GraphHPad 10.0 was used to create charts; the results were expressed as mean ± standard error (Mea ± SE). P < 0.01 was extremely significant, P < 0.05 was significant, and P > 0.05 was not significant.
[0138] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0139] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A strain of Lactobacillus paracasei LCQ-1, characterized in that The LCQ-1 deposit number is CGMCC NO.30466.
2. Use of Lactobacillus paracasei LCQ-1 according to claim 1 in preparing products for preventing and treating diarrhea.
3. The use of Lactobacillus paracasei LCQ-1 according to claim 1 in antagonizing pathogenic bacteria, characterized in that: The pathogenic bacteria are one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
4. The use of Lactobacillus paracasei LCQ-1 according to claim 1 in preparing a pathogenic bacteria antagonistic product, characterized in that: The pathogenic bacteria are one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
5. A drug for preventing and treating diarrhea, characterized in that: The method comprises the Lactobacillus paracasei LCQ-1 according to claim 1.
6. A drug for antagonizing pathogenic bacteria, characterized in that: The method comprises the Lactobacillus paracasei LCQ-1 according to claim 1; and the pathogenic bacteria are one or more of Escherichia coli, Enterococcus faecalis and Salmonella.
Citation Information
Cited By
Lactobacillus paracasei KQNIU, microbial preparation and application of lactobacillus paracasei KQNIU
CN121379903A
